Hypoglycemia Risk With Tirzepatide in Type 1 Diabetes: Emerging Clinical Evidence, Mechanistic Considerations, and Implications for Clinical Research

Title

Hypoglycemia Risk With Tirzepatide in Type 1 Diabetes: Emerging Clinical Evidence, Mechanistic Considerations, and Implications for Clinical Research

Publication Date

October 6, 2026

Author(s)

Dehn, C, Agarwal N, Ballester L, Beaton B, Eakin A, Gomez V, Lamas A, Martin W, McPherson KC, Saxby BK, Tireman E, Schwartz S

Record Type

Reports and Working Papers (White Paper)

DOI

TBD

Keywords:

Tirzepatide; Type 1 diabetes mellitus; Hypoglycemia; Insulin requirements

Abstract:

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, is not approved for treatment of type 1 diabetes (T1D). Nevertheless, use of tirzepatide in adults with T1D, particularly those who are overweight or obese, has increased in both clinical practice and investigational settings. The evidence base has evolved from small retrospective cohorts to a randomized phase 2 trial and recent systematic reviews. Across these sources, the most consistent findings are substantial weight loss, improved glycemic metrics, and reduced total daily insulin requirements. Importantly, the emerging tirzepatide-specific literature has not demonstrated a consistent increase in severe hypoglycemia or diabetic ketoacidosis (DKA), although the number of prospectively studied participants remains small and long-term safety is not established.1–7 The absence of a strong severe-hypoglycemia signal should not be interpreted to mean that hypoglycemia risk is absent. Tirzepatide is administered to individuals with T1D only in the presence of exogenous insulin. Current U.S. labeling warns that concomitant insulin can increase hypoglycemia risk and that insulin dose reduction may be necessary.8 The central clinical question is therefore not whether tirzepatide is intrinsically hypoglycemic, but how rapidly insulin requirements and nutrient appearance change after treatment and whether insulin delivery adapts appropriately. The broader GLP-1 receptor agonist (GLP-1RA) literature provides historical context. Large liraglutide trials in T1D demonstrated reductions in weight and insulin dose but also identified increased symptomatic hypoglycemia in some dose groups and increased hyperglycemia with ketosis at higher doses.9,10 More recent meta-analyses have generally not found a statistically significant increase in severe hypoglycemia with GLP-1RA adjunctive therapy, while gastrointestinal adverse effects and ketosis remain important considerations.11,12 For clinical research, continuous glucose monitoring (CGM) provides dense longitudinal glucose data that can characterize glycemic variability and detect the timing, magnitude, and duration of glucose excursions that may be missed by measurements collected at discrete time points. It should nevertheless be understood as one component of a broader safety and pharmacodynamic strategy. In studies involving early tirzepatide exposure, meal challenges, or gastric-emptying assessments, particular attention should be given to the temporal relationship among prandial insulin action, nutrient appearance, and glucose trajectories.